Introduction {#s1}
============

Autism spectrum disorder (ASD) is a type of complex neurodevelopmental disorder mainly characterized by stereotyped behavior and deficiency in social communication ability. Among children, the prevalence rate of ASD has been estimated to be 1 in 68 in the USA and 1 in 100 worldwide, and there is four times higher prevalence among boys than girls ([@B24]; [@B17]; [@B23]). ASD severely affects the life quality of patients and their families and increases public health burden ([@B25]). ASD patients exhibit highly heterogeneous clinical presentations, and ASD patients are mainly treated by rehabilitation intervention with no specific therapeutic drug ([@B8]). Therefore, it is necessary to understand the genetic mechanism underlying ASD development in important brain regions.

Genetic studies of ASD have revealed a number of risk loci that may contribute to ASD pathogenesis. It has been shown that single nucleotide polymorphisms (SNPs) located at loci 3p21 and 10q24, as well as in *CACNA1C* and *CACNB2*, are significantly associated with multiple psychiatric disorders including ASD ([@B15]). Xia et al. discovered *TRIM33* and *NRAS-CSDE1* as ASD candidate genes by GWAS analysis of Chinese autistic patients and datasets of three European populations ([@B63]). A recent study by the Autism Spectrum Disorders Working Group of the Psychiatric Genomics Consortium (PGC) identified multiple loci, composed of common variants, associated with ASD and found a significant genetic correlation between ASD and schizophrenia *via* meta-analysis of more than 16,000 autistic patients ([@B52]). Furthermore, Cantor et al. found that rs289883 located in the intron of gene *PHB* was associated with the degree of behavioral abnormality in ASD patients ([@B12]).

Different brain regions control different functions, which may be impaired in ASD patients. The frontal lobe of the brain plays an important role in social, emotional, and cognitive functions and has shown severe dysfunction in ASD patients ([@B14]). The frontal lobes in ASD patients undergo an abnormal overgrowth while other regions are not significantly enlarged ([@B11]). Additionally, a decrease in astrocyte precursor cells and an increase in synaptic connectivity are observed in the frontal cortex of ASD patients ([@B10]). Previous studies demonstrated pronounced ASD-associated gene expression changes in the cerebral cortex, including attenuated distinction between the frontal and temporal cortices in ASD brains ([@B56]).

Because of the importance of the frontal cortex in normal brains and its dysfunction in ASD brains, we aim to identify targeted genes of ASD risk loci in the frontal cortex. We obtained ASD associated SNPs from the GWAS catalog and found genes with genotype-correlated expression in the frontal cortex tissue from eQTL databases. By analyzing microarray gene expression datasets, we then identified 76 ASD--loci correlated genes showing significant expression difference between ASD brain frontal cortices and controls, and we further replicated four genes in an RNA-seq dataset. Among the ASD GWAS SNPs correlating with the 76 genes, 20 overlap with histone marks and 40 were associated with the gene methylation level, suggesting that they may regulate the transcription of their target genes through epigenetic mechanisms. Our results help to understand how ASD GWAS loci confer disease risk and prioritize genes for further functional validation.

Material and Methods {#s2}
====================

Extraction of ASD GWAS Loci {#s2_1}
---------------------------

Significant ASD associations were downloaded from the GWAS catalog (<https://www.ebi.ac.uk/gwas/>) ([@B39]) using the keyword "autism spectrum disorder," and SNP information was extracted from downloaded data. We did not apply any significance threshold when extracting ASD SNPs from the GWAS catalog.

eQTL Analysis {#s2_2}
-------------

Genes with expression in the frontal cortex that correlate with the genotypes of ASD SNPs were extracted from two eQTL databases: GTEx (<https://gtexportal.org/home/>) ([@B26]) and Braineac (<http://caprica.genetics.kcl.ac.uk/BRAINEAC/>) ([@B45]). Only associations with *P* \< 0.05 were extracted.

Analysis of Microarray Data {#s2_3}
---------------------------

Series matrix files of two microarray datasets GSE28475 ([@B13]) and GSE28521 ([@B56]) that compare transcriptome data in human brain frontal cortex between ASD cases and controls were downloaded from the Gene Expression Omnibus (GEO) database (<https://www.ncbi.nlm.nih.gov/geo/>) ([@B6]). There are 16 ASD cases and 16 controls in dataset GSE28521, and there are 52 cases and 61 controls in dataset GSE28475. Microarray data underwent quality control with log2 transformation and quantile normalization. Differential expression analysis was performed using the linear regression approach (Limma model) and further meta-analyzed using Fisher's method in the NetworkAnalyst portal (<http://www.networkanalyst.ca/>) ([@B62]) with adjustment for batch effects.

Analysis of RNA-Seq Data {#s2_4}
------------------------

The SRA file of an RNA-seq dataset (GSE102741) ([@B61]), which similarly compares transcriptome data in human brain frontal cortex between ASD cases and controls, was downloaded from the GEO database. Dataset GSE102741 contains 13 ASD cases and 39 controls. The quality of RNA-seq raw reads was examined using FastQC ([@B1]), and reads were aligned to the human reference genome (GRCh37) using software HISAT2 ([@B34]). Then transcripts were assembled and quantified using Stringtie ([@B44]) with the reference gene annotation (GRCh37) as a guide. Differential expression analysis between cases and controls was conducted using edgeR ([@B48]).

Protein--Protein Interaction Network Analysis {#s2_5}
---------------------------------------------

The gene symbols were input into the NetworkAnalyst web portal, which maps each gene to protein--protein interaction (PPI) databases to construct networks. The PPI network was constructed among the 76 genes without further extension, with InnateDB ([@B9]) as the source of protein interactions.

Pathway Enrichment Analysis {#s2_6}
---------------------------

We input the 76 genes into DAVID (<https://david.ncifcrf.gov/home.jsp>) ([@B30]) and PANTHER (<http://www.pantherdb.org/>) ([@B41]) web portals for pathway analysis. The pathway databases used in our analyses are KEGG (Kyoto Encyclopedia of Genes and Genomes) ([@B33]) and Reactome ([@B21]), respectively.

Analysis of Methylation Data {#s2_7}
----------------------------

The generation of genome-wide methylation profiles of 843 subjects on the Infinium HumanMethylation450 BeadChip by the Center for Applied Genomics, the Children's Hospital of Philadelphia, was reported in a previous publication ([@B54]). The methylation level of each methylation probe was represented by the *M*-values (the log2 ratio between the methylated and unmethylated probe intensities). The association of ASD GWAS SNPs with methylation probes in each of the 76 genes was assessed in a linear regression model including gender, age, and 10 genotype-derived principle components as covariates.

Hi-C Data Visualization {#s2_8}
-----------------------

We conducted Hi-C data visualization for the ASD loci and target genes through the 3D Genome browser (promoter.bx.psu.edu/hi-c/) ([@B57]) and the FUMA GWAS site (<http://fuma.ctglab.nl/>) ([@B59]) using reported brain Hi-C data ([@B50]; [@B60]).

Results {#s3}
=======

As the frontal cortex is involved in important brain functions, which are severely impaired among ASD patients (communication, language, social behavior, and complex cognitive functions), we are interested in identifying target genes of ASD risk loci in the frontal cortex region. To do this, we first extracted all reported ASD associated risk loci from the GWAS catalog. A total of 466 SNPs from 19 studies were extracted, with the highest reported association *P*-value of 1 × 10^−5^. The majority (97%) of these SNPs were located in non-coding regions. As these non-coding SNPs could function by regulating downstream target gene expression, we examined their potential regulatory effects in two eQTL databases \[brain---frontal cortex tissue in the GTEx database ([@B26]) and frontal cortex in the Braineac database ([@B45])\].We found 457 genes from GTEx and 1,848 genes from Braineac with mRNA level correlated with the additive genotype of ASD GWAS SNPs (nominal *P* \< 0.05). As GWAS loci and their targeted genes may not exhibit highly significant correlations in eQTL analysis, we took this less stringent threshold and combined the ASD--loci targeted genes from the two datasets, yielding a list of 2,098 genes. The eQTL associations suggest that the expression of these genes may be directly or indirectly influenced by the genotype of the ASD loci.

We hypothesized that the expression of genes functioning in the frontal cortex may be dis-regulated among ASD patients; thus, we conducted gene expression meta-analysis by comparing the mRNA level of ASD cases and that of healthy controls at the genome-wide scale using datasets GSE28475 and GSE28521 from the GEO database. The analysis yielded 893 differentially expressed genes (adjusted *P* \< 0.05). Among the 2,098 genes likely regulated by ASD--loci, 76 displayed significant differential gene expression ([**Supplementary Table 1**](#SM1){ref-type="supplementary-material"}), implicating that these genes may be ASD loci-controlled genes in the frontal cortex.

As replication, we looked into ASD RNA-seq dataset GSE102741 in the GEO database. We similarly conducted transcriptome profiling analysis and found that four of the 76 genes identified in the above steps showed significant differences (*P* \< 0.05) in mRNA level between ASD cases and healthy controls: *HIST1H1C*, *HSPA1B*, *PRPF3*, and *SERPINA3* ([**Table 1**](#T1){ref-type="table"}). Therefore, differential expression of these four genes in the frontal cortex of ASD brains were further validated by RNA-seq. Inability to validate the remaining 72 genes could be due to the small sample size of the RNA-seq dataset. We further checked brain Hi-C data and found additional supporting evidence for the plausible chromatin interactions between ASD SNPs and the target genes ([**Supplementary Figure 1**](#SM1){ref-type="supplementary-material"}). Certainly, future Hi-C experiments specifically focusing on the frontal cortex regions should be performed to examine these interactions. It has been reported in the human protein atlas database (<https://www.proteinatlas.org/>) ([@B53]) that both the mRNA and proteins of ASD target genes *HIST1H1C* and *PRPF3* were detected in human brain cerebral cortex; HIST1H1C protein level is particularly high. The HSPA1B protein and SERPINA3 mRNA were also detected in the cerebral cortex. By searching the Mouse Genome Informatics (MGI) database (<http://www.informatics.jax.org>) ([@B35]), we also found that mRNA of mouse HIST1H1C and PRPF3 homologues has been detected in mouse brains in previous publications ([@B40]; [@B18]). Furthermore, abnormal behavior, neurological phenotype, or defects in nervous system have been documented for mouse strains carrying mutant Prpf3 or Hspa1b genes ([@B35]), suggesting the biological relevance of these genes to ASD.

###### 

Candidate autism spectrum disorder (ASD) target genes that showed significant differential expression in both microarray and RNA-seq datasets.

  ASD SNP      Target gene   eQTL *P*-value   Microarray *P*-value   RNA-seq *P*-value
  ------------ ------------- ---------------- ---------------------- -------------------
  rs75782365   *HIST1H1C*    0.0015           0.0316                 0.0228
  rs3132581    *HSPA1B*      0.0058           0.0121                 0.00299
  rs11587682   *PRPF3*       0.017            0.0145                 0.0325
  rs4905226    *SERPINA3*    0.014            0.0376                 0.00629

SNP, single nucleotide polymorphism; Target Gene, candidate target gene identified for each ASD GWAS locus; eQTL P-value, P-value of correlation between gene expression level and GWAS SNP genotype in GTEx database or Braineac database; Microarray P-value, P-value of the differentially expressed gene in microarray meta-analysis; RNA-seq P-value, P-value of the differentially expressed gene in RNA-seq analysis.

To understand how the 76 genes are involved in ASD pathogenesis, we constructed a protein--protein interaction (PPI) network ([**Figure 1**](#f1){ref-type="fig"}) using NetworkAnalyst. The largest module consists of 11 of the 76 genes, including three of the RNA-seq validated genes (*HIST1H1C*, *HSPA1B*, and *SERPINA3*). To fully understand the interactions between these genes, we further examined the pathways in which these genes are enriched. We found significantly enriched pathways: "Antigen processing and presentation" and "Noncanonical activation of NOTCH3" ([**Supplementary Table 2**](#SM1){ref-type="supplementary-material"}). Both of these pathways are highly relevant to ASD pathogenesis ([@B43]; [@B29]; [@B7]; [@B31]).

![Eleven out of 76 proteins encoded by the autism spectrum disorder (ASD) loci target genes showed protein--protein interactions (PPIs). The PPI network was constructed using NetworkAnalyst with InnateDB as the source of protein interaction data. The nodes represent proteins, and the size of the nodes reflects the number of interaction partners with it. The edges between the nodes indicate known interactions between the proteins.](fgene-10-00707-g001){#f1}

Both phenotypic and genetic overlap was observed between neuropsychiatric diseases. We found that SNPs in genes *HISTI1H1C*, *HSPA1B*, *PRPF3*, and *SERPINA3* showed at least nominal significant association with four other neuropsychiatric diseases \[schizophrenia (SCZ), bipolar disorder, major depressive disorder (MDD), and attention-deficit hyperactivity disorder (ADHD)\] in the Broad PGC database (<https://data.broadinstitute.org/mpg/ricopili/>) ([@B46]) ([**Table 2**](#T2){ref-type="table"}).

###### 

Within genes *HISTI1H1C*, *HSPA1B*, *PRPF3*, and *SERPINA3*, single-nucleotide polymorphisms (SNPs) are associated with other neuropsychiatric diseases.

               ADHD         Bipolar   MDD          SCZ                                            
  ------------ ------------ --------- ------------ ---------- ------------ --------- ------------ ----------
  *HIST1H1C*   rs16891264   0.0529    rs10425      0.0022     rs12210098   0.0024    rs3857546    1.46E−09
  *HSPA1B*     rs9267786    0.0202    rs389883     0.000322   rs9368699    0.00562   rs1270942    5.00E−07
  *PRPF3*      rs10494266   0.00081   rs12138453   0.000171   rs16836940   0.00014   rs16835254   0.000105
  *SERPINA3*   rs2268336    0.00107   rs17091191   0.00103    rs1243533    0.0162    rs11625527   0.00403

ADHD, attention-deficit hyperactivity disorder; MDD, major depressive disorder; SCZ, schizophrenia.

To understand how ASD SNPs may regulate the expression of their target genes, we explored the functional annotations of ASD GWAS SNPs corresponding to the 76 target genes in the ENCODE ([@B20]) and ROADMAP ([@B47]) epigenome databases *via* the HaploReg web portal ([@B58]). We found 20 ASD SNPs overlap with histone marks in the brain dorsolateral prefrontal cortex ([**Table 3**](#T3){ref-type="table"}). This suggests that these SNPs may affect chromatin activation through histone methylation and acetylation, which in turn affects their target gene expression.

###### 

ASD genome-wide association studies (GWAS) SNPs overlap with histone marks in brain dorsolateral prefrontal cortex, based on ENCODE and ROADMAP datasets.

  SNP          Chromatin marks                       
  ------------ ----------------- --------- --------- --------
  rs1080500                      H3K4me1   H3K27ac   
  rs1104918                      H3K4me1   H3K27ac   
  rs12045323                     H3K4me1   H3K27ac   
  rs12826178                     H3K4me1             
  rs133047                       H3K4me1             
  rs1550976                      H3K4me1             
  rs169738     H3K4me3           H3K4me1   H3K27ac   
  rs17292804   H3K4me3           H3K4me1   H3K27ac   H3K9ac
  rs2021722                      H3K4me1   H3K27ac   H3K9ac
  rs2233375                                H3K27ac   
  rs2297909                      H3K4me1   H3K27ac   H3K9ac
  rs2898883                                H3K27ac   H3K9ac
  rs4150167                      H3K4me1   H3K27ac   
  rs4702       H3K4me3           H3K4me1   H3K27ac   H3K9ac
  rs548181     H3K4me3           H3K4me1   H3K27ac   H3K9ac
  rs609412                       H3K4me1             
  rs73416724   H3K4me3           H3K4me1   H3K27ac   H3K9ac
  rs760648                       H3K4me1             
  rs8321                         H3K4me1             H3K9ac
  rs880446     H3K4me3           H3K4me1   H3K27ac   H3K9ac

We also looked into whether there is any correlation between the genotypes of ASD SNPs and methylation at or near their target genes. Forty-five of the 76 genes contained probes with methylation level correlated with additive SNP genotype ([**Table 4**](#T4){ref-type="table"}) at a nominal significance level, suggesting that the expression level of these genes may be regulated by ASD SNPs through DNA methylation.

###### 

ASD GWAS SNPs correlate with target gene methylation level at nominal significance level.

  eQTL_SNP     Gene         Methylation probe   Methylation beta   Methylation *P*-value
  ------------ ------------ ------------------- ------------------ -----------------------
  rs385492     *HLA-F*      cg09296453          −0.204             1.25E−16
  rs12887734   *ZFYVE21*    cg01651570          0.33               9.61E−07
  rs4650608    *IFI44*      cg07107453          −0.0964            3.93E−06
  rs2021722    *HLA-A*      cg20408505          −0.0653            0.000391
  rs8054556    *SEZ6L2*     cg09584855          0.0426             0.000398
  rs7746199    *PGBD1*      cg20029652          0.0364             0.000721
  rs1080500    *SELK*       cg02011912          0.0449             0.000883
  rs11587682   *APH1A*      cg04633021          −0.0633            0.00107
  rs880446     *TCEA2*      cg03946671          −0.141             0.00162
  rs1550976    *NTM*        cg04307764          −0.0481            0.00208
  rs4150167    *HSDL1*      cg08941639          −0.253             0.00223
  rs2332700    *RGS6*       cg12963168          0.0372             0.00239
  rs2535629    *ABHD14A*    cg09254361          0.0693             0.00261
  rs221902     *MED6*       cg16339264          0.033              0.00265
  rs11191419   *ACTR1A*     cg11453585          −0.0485            0.00329
  rs11587682   *PRPF3*      cg04212235          0.106              0.00405
  rs6538761    *LTA4H*      cg09725090          0.0222             0.00502
  rs12871532   *LIG4*       cg20776540          −0.0244            0.00547
  rs11587682   *MCL1*       cg17724175          0.108              0.00597
  rs72934570   *WDR7*       cg24533565          −0.0718            0.00636
  rs880446     *ZBTB46*     cg04630273          0.0518             0.00655
  rs8009147    *ADSSL1*     cg21190363          0.0317             0.00854
  rs8321       *ABCF1*      cg05385119          0.148              0.00896
  rs1080500    *CACNA2D3*   cg09890989          0.0324             0.0116
  rs4773054    *COL4A1*     cg02673355          0.0716             0.0118
  rs609412     *LARS*       cg17175376          0.022              0.0128
  rs169738     *NUDT3*      cg25055477          0.0178             0.0152
  rs2851447    *HIP1R*      cg26682900          −0.0185            0.0167
  rs548181     *SRPR*       cg27218829          −0.0302            0.0202
  rs72687362   *ARC*        cg08860119          −0.0361            0.0215
  rs7914558    *SH3PXD2A*   cg07168060          0.0332             0.0217
  rs2233375    *INPP5D*     cg12315466          0.034              0.0226
  rs12826178   *SHMT2*      cg08163918          −0.133             0.025
  rs548181     *HYLS1*      cg21050392          −0.0281            0.0281
  rs10255295   *ZC3HAV1*    cg14341575          0.034              0.0287
  rs1797052    *POLR3C*     cg19990379          −0.0364            0.0306
  rs3849046    *REEP2*      cg07368507          0.0279             0.0308
  rs1104918    *AEN*        cg21347380          −0.0318            0.0371
  rs6453278    *AGGF1*      cg15817406          −0.0526            0.0384
  rs7254215    *NOTCH3*     cg01282080          −0.0401            0.0388
  rs7184114    *GPR56*      cg25645462          −0.0301            0.0396
  rs11735612   *PCDH18*     cg06787716          −0.0219            0.0398
  rs2898883    *SPOP*       cg08001899          0.0471             0.0412
  rs133047     *XRCC6*      cg26919805          0.0557             0.0428
  rs73416724   *MRPL2*      cg01847614          −0.0244            0.0456

Discussion {#s4}
==========

To find ASD GWAS loci targeted genes, we conducted an analysis integrating eQTL, transcriptome, epigenome, and methylation data. We began by analyzing the correlation between SNP genotype and mRNA level of genes reflected by eQTL data, and we obtained 2,098 target genes that may be regulated by these ASD loci. Then, we analyzed the differentially expressed genes between cases and controls at the mRNA level using array and RNA-seq data. A total of 76 genes with expression correlating with ASD SNP genotype were differentially expressed between ASD cases and controls in the frontal cortex in array data. Four of those genes were further validated by RNA-seq data. Evidence also suggested that the expression level of these genes could be regulated through histone modification or DNA methylation. Therefore, by *in silico* analysis, we identified candidate genes likely controlled by ASD loci in the frontal cortex, which are worthy of further experimental validation.

There are multiple lines of evidence suggesting the involvement of the four candidate ASD genes in disease etiology. *HIST1H1C* encodes a protein that belongs to the histone cluster 1 H1 family. In an ASD model system based on haploinsufficiency of *SHANK3*, Darville et al. found that five histone isoforms including HIST1H1C were down-regulated upon lithium and VPA treatment in neurons differentiated from pluripotent stem cells. Lithium and VPA increased levels of *SHANK3* mRNA, and the authors speculated that *SHANK3* may be regulated through an epigenetic mechanism involving histone modification ([@B16]). In addition, *HIST1H1C* may also be involved in other brain disease development. For example, *HIST1H1C* displayed consistently significant increased mRNA level in the cortex of brains from 7- and 18-month-old mice in an Alzheimer's disease model ([@B27]). The mRNA level of *HIST1H1C* is up-regulated in hypoxia and is correlated with worse disease outcome among neuroblastoma patients ([@B2]). Mutation in other members of histone cluster 1 H1 family, such as HIST1H1E, has been detected in ASD patient and is likely to be the underlying causal mutation ([@B19]). Systematic review indicated that nearly 20% of ASD candidate genes play a role in epigenetic regulations, especially histone modifications ([@B19]). These data support the potential involvement of HIST1H1C in ASD development, likely through epigenetic regulation of neurodevelopmental genes.

*HSPA1B* encodes a heat shock protein, which works as chaperone for other proteins. In heat shock experiments on induced pluripotent stem cells modeling brain development under maternal fever, *HSPA1B* is one of the heat shock genes that drastically increased its mRNA level, together with other genes involved in neurogenesis and neuronal function ([@B37]). Heat shock proteins target mis-folded proteins and facilitate proper refolding or targeting of damaged proteins for degradation ([@B37]). Its mRNA level is increased in the frontal cortex of schizophrenia subjects ([@B3]). It has been shown that *HSPA1B* also functions in the pathogenesis of other neurological conditions, such as Parkinson disease ([@B32]), progressive supranuclear palsy ([@B28]), and Alzheimer's disease ([@B51]; [@B42]), presumably by facilitating protein folding and inhibiting apoptosis ([@B36]). Genes enriched in multiple signaling pathways, like pathways of "Heterotrimeric G-protein signaling pathway" and "B cell activation," were altered by Hspa1b deficiency in an MPTP-induced mouse model of Parkinson disease ([@B5]).

PRPF3 is one of several proteins interacting with U4 and U6 small nuclear ribonucleoproteins, which are components of spliceosomes. Mutations in *MECP2* (methyl-CpG-binding protein 2) cause the neurodevelopmental disorder Rett syndrome. The MECP2 protein directly interacts with PRPF3 ([@B38]), and several Rett-associated mutations in *MECP2* affect interaction of MECP2 with PRPF3, implying that neurodevelopmental disorders, in general, could be related to abnormal mRNA splicing.

*SERPINA3* belongs to the serine protease inhibitor family. The protein antagonizes the activity of neutrophil cathepsin G and mast cell chymase and has been implicated in neuroinflammation, neurodegeneration ([@B4]), and other types of brain conditions such as human prion diseases ([@B55]). The mRNA level of SERPINA3 is robustly up-regulated in the prefrontal cortex of schizophrenia patients, suggesting its involvement in the pathogenesis of neuropsychiatric disorders ([@B3]; [@B49]; [@B22]).

In summary, we identified genes that may function as ASD genetic loci targeted genes in the brain frontal cortex through multi-omics data analyses. These genes are worth being further characterized for their function in ASD development through experimental approaches.
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